![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
In his thoughtful response to my essay “Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies?” Reed has made a number of valid and important points. The “costs” I described (drug acquisition costs for the chemotherapeutic and bone marrow colony-stimulating agents) clearly represent only one component of the “costs” associated with chemotherapy. In addition, there are a number of examples where “expensive medications” (e.g., effective antibiotics; bone marrow colony-stimulating agents in patients undergoing autologous bone marrow transplantation) significantly reduce the overall cost of medical care associated with a specific medical condition.